Reaction

Portal Vein Thrombosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,178 reports · 103 co-occurring drugs

As of the last recalculation, Portal Vein Thrombosis appears in 3,178 FAERS reports alongside 103 co-occurring drug terms. The strongest observed disproportionality signal is NEVIRAPINE (PRR 40.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nevirapine	55	40.6	40.9
Sofosbuvir	73	24.8	24.9
Sorafenib	66	21.2	21.3
Entecavir	35	19.8	19.9
Drospirenone And Ethinyl Estradiol	126	19.4	19.5
Atezolizumab	111	19.4	19.4
Abacavir Sulfate	25	16.9	17.0
Zidovudine	33	16.3	16.4
Romiplostim	37	16.3	16.3
Tenofovir Disoproxil Fumarate Tablets	21	16.0	16.1
Eltrombopag Olamine	53	15.3	15.3
Dalteparin Sodium	22	13.7	13.7
Lamivudine Oral	52	13.7	13.7
Testosterone	48	13.6	13.7
Etonogestrel And Ethinyl Estradiol	43	12.9	12.9
Efavirenz	21	12.4	12.4
Fondaparinux Sodium	15	12.2	12.2
Lamivudine	56	12.1	12.1
Ritonavir 100 Mg	26	11.5	11.5
Bevacizumab	194	10.9	10.9
Lenvatinib	52	10.5	10.6
Irinotecan Hydrochloride	20	10.2	10.3
Ribavirin	95	9.9	10.0
Ursodiol	32	9.7	9.7
Oxaliplatin	104	9.5	9.5
Ritonavir	41	9.3	9.3
Rifaximin	27	8.5	8.5
Ursosiol	25	8.5	8.5
Fluorouracil Cream, 0.5%	95	8.4	8.4
Fluorouracil	95	8.3	8.3
Atazanavir	18	8.2	8.3
Ledipasvir And Sofosbuvir	23	7.9	7.9
Basiliximab	14	7.8	7.8
Sirolimus	16	7.8	7.8
Panitumumab	18	7.6	7.6
Hydroxyurea	24	7.5	7.5
Fulvestrant	37	7.4	7.4
Gemcitabine Hydrochloride	59	7.4	7.4
Lactulose	42	7.3	7.3
Durvalumab	22	7.1	7.1
Micafungin Sodium	9	7.0	7.0
Busulfan	16	6.7	6.7
Loperamide Hcl	13	6.6	6.6
Tacrolimus	148	6.4	6.4
Loperamide Hydrochloride Oral	10	6.4	6.4
Everolimus Tablets	16	6.3	6.3
Gemcitabine	37	6.2	6.2
Leucovorin Calcium	18	6.2	6.2
Thiotepa	9	6.2	6.2
Tacrolimus Ointment 0.1%	114	6.2	6.2
Tacrolimus Extended-Release Capsules	114	6.2	6.2
Velpatasvir And Sofosbuvir	12	6.1	6.1
Darunavir	14	6.1	6.1
Eculizumab	47	5.7	5.7
Heparin Sodium	12	5.7	5.7
Capecitabine	78	5.7	5.7
Meropenem	26	5.3	5.3
Pancrelipase	31	5.3	5.3
Amphotericin B	10	5.2	5.2
Cetuximab	24	5.0	5.1
Tenofovir Disoproxil Fumarate	25	5.0	5.0
Spironolactone	104	5.0	5.0
Anti-Thymocyte Globulin (Rabbit)	6	4.9	4.9
Lopinavir And Ritonavir	10	4.8	4.8
Propranolol Hydrochloride	52	4.8	4.8
Ado-Trastuzumab Emtansine	6	4.7	4.7
Tolvaptan	10	4.5	4.5
Tranexamic Acid	6	4.4	4.4
Granisetron Hydrochloride	7	4.4	4.4
Granisetron	7	4.4	4.4
Raltegravir	11	4.4	4.4
Cisplatin	49	4.2	4.2
Cetirizine Hydrochloride Allergy	19	4.1	4.1
Cetirizine Hydrochloride Tablets	19	4.1	4.1
Baricitinib	6	4.1	4.1
Mesna Injection	5	4.0	4.0
Mesna	5	3.9	3.9
Apixaban	38	3.8	3.8
Testosterone Cypionate	5	3.7	3.7
Erlotinib Hydrochloride	7	3.7	3.7
Paclitaxel	53	3.5	3.5
Lanreotide Acetate	4	3.3	3.3
Ruxolitinib	36	3.3	3.3
Abemaciclib	10	3.3	3.3
Blinatumomab	5	3.1	3.1
Peginterferon Alfa-2A	25	3.0	3.0
Sunitinib Malate	18	3.0	3.0
Ipilimumab	19	2.9	2.9
Rocuronium Bromide	5	2.8	2.8
Ifosfamide	9	2.7	2.7
Erlotinib	4	2.7	2.7
Docetaxel Anhydrous	26	2.5	2.5
Docetaxel	26	2.5	2.5
Rucaparib	3	2.2	2.2
Lapatinib	5	2.1	2.1
Nivolumab	31	2.1	2.1
Cabozantinib	15	2.0	2.1
Ravulizumab	4	1.9	1.9
Trifluridine And Tipiracil	3	1.8	1.8
Glecaprevir And Pibrentasvir	3	1.8	1.8
Palivizumab	4	1.7	1.7
Minoxidil Foam 5% (Womens)	8	1.6	1.6
Minoxidil	8	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.